Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest gaining 'relevant' GI position with Furiex buy

This article was originally published in Scrip

Executive Summary

Just because Actavis will pay $25bn to acquire Forest Laboratories, that doesn't mean New York-based Forest's own acquisitive streak is coming to an end, as evidenced by the company's latest investment – at least $1.1bn to buy Furiex Pharmaceuticals.

You may also be interested in...



Allergan's Big Deal: A Buyout, Not A Split, Appeases Wary Investors

Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.

Allergan’s Namesake Acquisition Looks Well-Timed As Established Brands Falter

Allergan’s net product revenue in the third quarter fell slightly below analyst consensus, but revenue from the company’s 2015 purchase of Botox, Restasis and other products softened declines for established products Namenda and Asacol.

Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn

Allergan will pay a huge premium – up to $1.7bn in a milestone-heavy deal – for Tobira and $50m up front for the preclinical startup Akarna to expand its gastrointestinal franchise into the potentially lucrative NASH market.

Topics

Related Companies

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel